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REVIEWLearning About Oxytocin: Pharmacologic and
Behavioral Issues
Bice Chini, Marianna Leonzino, Daniela Braida, and Mariaelvina SalaDespite the accumulating evidence suggesting that the neuropeptide oxytocin (OT) plays a role in neuropsychiatric disorders
characterized by social dysfunction, the inﬂuence of OT on the nonsocial aspects of learning and memory have been less investigated.
To foster research in this area, we review the effects of OT on learning and memory in animal models and humans. In healthy animal
models, OT improves memory consolidation and extinction, but only if given at a low dose immediately after the acquisition phase. On
the contrary, OT effects in healthy humans have been inconsistent; although, in this case, OT was always given before the acquisition
phase and no dose-response curves have ever been drawn up. Interestingly, a speciﬁc impairment in the reversal of learning has been
found in mice devoid of OT receptors and OT has been demonstrated to enhance fear extinction in rodents. All together, these data
suggest that OT plays a role in elementary forms of behavioral ﬂexibility and adaptive responses and support its therapeutic potential in
neuropsychiatric disorders characterized by cognitive inﬂexibility and/or impairment (autism, schizophrenia, Alzheimer’s disease,
Parkinson disease, stroke, posttraumatic stress disorder). Accordingly, OT has been shown to improve cognitive ﬂexibility in OT receptor-
deﬁcient mice, and scattered ﬁndings indicate that intranasal OT has positive effects on the memory of patients with schizophrenia
or posttraumatic stress disorders. Further studies of the therapeutic potential of OT as an enhancer of learning and memory are warranted.Key Words: Animal models, consolidation, ﬂexibility, learning and
memory, neuropeptide, neuropsychiatric disorders, oxytocin
This review will concentrate on aspects of learning andmemory other than social behavior and social cognition,because the involvement of oxytocin (OT) in shaping and
regulating the social brain have been extensively covered by a
number of excellent and exhaustive reviews (1–4). It ﬁrst reviews
experimental data relating to learning and memory paradigms in
animal and humans and then summarizes what is known about
its neurochemical substrates in rodents. Finally, it discusses a few
critical issues in the hope of encouraging the successful ther-
apeutic use of OT in neuropsychiatric disorders.
Oxytocin in Learning and Memory
Animal Studies
Table 1 and Tables S1 and S2 in Supplement 1 provide a
comprehensive overview of all of the reviewed papers describing
the administration of OT to animal models (mainly rodents, but
also birds and molluscs). Table 1 shows the studies reporting
enhanced learning and memory (5–10), while Table S1 and Table
S2, respectively, in Supplement 1 show the studies reporting
impaired learning and memory (6,11–21) or no effect
(10,13,15,22–27). Most papers consider the effects of OT on
learning and memory in mice and rats, but ﬁndings in elderly
monkeys indicate that OT (4–128 μg/kg) subcutaneously (SC)
administered 30 minutes before the task impaired memory in
three of the six but led to subtle but replicable improvements in
the number of correct choices in two monkeys (28). It is surprising
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which are among the most widely used models for investigating
the biological roots of mating and other social behaviors (29).
Furthermore, although few data are available concerning other
species, the ﬁndings in birds (pigeons and chicks) and molluscs
(Sepia ofﬁcinalis) are in line with those of rodents. These studies
have led to the development of a vasopressin (AVP)/OT central
memory theory that suggests AVP enhances and OT inhibits
memory consolidation and retrieval. However, the exact involve-
ment of these molecules in learning and memory is still very
controversial (30), mainly because the experiments have used
different doses and administration routes. Furthermore, learning
and memory processes involve many distinct phenomena that
can be distinguished on the basis of the stimulus (spatial,
aversive, or rewarding), context (nonsocial, social), and/or timing
(acquisition, consolidation, retention, extinction, recall).
Dosage. As has often been observed in behavioral studies, the
dose-response curves of OT’s effects have an inverted-U shape.
In mice and rats, a moderate OT dose (100–300 ng/kg) impairs
passive avoidance, whereas lower (10 or 30 ng/kg) or higher
doses (1000 ng/kg) have no effect (13,16). Similarly, the extinction
phase of pole-jumping behavior is inhibited by high SC doses
of OT (1000–3000 ng per rat) given during consolidation, whereas
lower doses (1000 ng) have no effect or tend to facilitate
extinction (6). Oxytocin has a biphasic effect on social behavior:
very low peripheral doses (in the pg-ng/kg range) improve social
memory but higher (μg-mg/kg) doses disrupt it (31–35). Finally,
the intracerebroventricular (ICV) administration of the selective
OT agonist [Thr4,Gly7]-oxytocin to Oxtr/ mice improves social
recognition deﬁcit at a dose of .0005 ng/mouse, whereas higher
doses (.005–.5 ng/mouse) and a lower dose (.00005 ng/mouse) do
not (35). The U-shaped, biphasic, or even more complex dose-
response curves may be due to various factors. High doses of OT
may activate AVP V1a and/or V1b receptors, as observed in Oxtr/
and Oxtr/ mice (36,37), and the release of other neuro-
transmitter/hormone systems may be modulated. When given
before extinction, OT delays fear conditioning extinction in rats in
a bimodal manner, depending on the levels of corticosterone
released (16), whereas AVP has no signiﬁcant effect on the
corticosterone response to noise stress (38). Finally, some of the
studies cited above used very high doses of OT peripherallyBIOL PSYCHIATRY 2014;76:360–366
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Table 1. Improving Effect of OT on Memory in Different Tasks
Species Route Dose Test
Affected
Memory Phase Reference
Male Mice SC .1 ng/kg Novel object recognition Consolidation (5)
Rats SC .01 ng Passive avoidance Consolidation (6)
Sepia Ofﬁcinalis Peripheral 300060000 ng/kg Passive avoidance Consolidation (7)
Chicks Intracerebral 5 pg–50 ng Conditioned taste aversion Consolidation (8)
Wistar Rats DSN .05 ng Passive avoidance Consolidation (9)
Virgin Female Mice ICV 2 ng for 12 days Radial maze Long-term memory (10)
DSN, dorsal septal nuclei; ICV, intracerebroventricular; OT, oxytocin; SC, subcutaneous.
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the risk of interfering with overall behavioral performance,
whose integrity is essential in all memory paradigms. In this
regard, it has been reported that a very high peripheral dose of
3000 ng per rat signiﬁcantly reduces all measures of general
activity (6), as conﬁrmed by our unpublished data indicating that
1 ng per mouse ICV reduces general arousal. The effective dose
on any speciﬁc behavioral parameter should be experimentally
ruled out on the basis of carefully planned dose-response
curves.
Administration Routes. Two important issues that need to be
clariﬁed is whether peripherally administered OT reaches the
brain because of its very limited passage through the blood/brain
barrier (BBB) (39), and the brain OT levels required to have a
mnemonic effect. Small amounts of OT may cross the BBB (40),
and it has been calculated that .002% of SC or intravenous OT
reaches the cerebrospinal ﬂuid (CSF) of freely moving rats within
10 minutes of administration. However, after 30 years of research,
there is still no irrefutable proof that peripherally administered OT
(and related peptides) actually does cross the BBB: for example,
there is intense controversy as to whether this is true of
intranasally administered OT and AVP, and two papers reported
conﬂicting results in the space of 2 months in 2013 (41,42).
However, although the mechanisms by which peripherally
administered OT acts within the brain are not known, there is
no doubt that central effects are observed after intranasal, SC,
and intravenous administration in various animal species. Animal
studies of the intranasal route (the preferred route in humans)
have only considered social behavior, but it is interesting to note
that 25 IU of OT intranasally administered to rhesus macaques
increased the frequency of prosocial choices associated with
reward to another monkey 2 hours after inhalation (43), and in
the same study, CSF OT levels doubled within 35 minutes (43),
thus supporting the idea that endogenous OT in the CSF comes
from central and not peripheral sources. In prairie voles, the acute
effects of intranasal OT resemble those found in many human
studies (an increase in prosocial behavior and engagement), but
when given for 21 days at three doses (.08, .8 or 8.0 IU/kg), it
impaired the formation of pair-bond behavior (44) and this
detrimental social consequence persisted far longer than the
treatments themselves.
It is very difﬁcult to estimate the brain OT levels required to
have an effect on memory. It has been shown that an ICV
injection of 1 pg can begin to restore social memory deﬁcit in
Oxt/ mice, although better results are obtained using 1 ng (45).
Accordingly, a very low SC dose (.1 ng/kg) improves the
consolidation of episodic memory in mice engaged in the object
recognition task (5). Unfortunately, no data are available con-
cerning OT levels during memory tasks.Learning Paradigms and Phases of Memory. An important
ﬁnding is that OT does not appear to play a key role in spatial
learning because the acquisition phase of spatial memory is not
impaired in Oxt/ mice evaluated using the Morris water or a
two-trial Y-maze (46), and Oxtr/ mice and their wild-type
littermates have similar spatial memory acquisition rates when
performing an appetitive-motivated T-maze task (36). Accord-
ingly, repeated injections of OT (2 ng ICV for 12 days) do not
impair short-term memory in virgin female mice undergoing a
radial maze task (10). However, in the same experimental setting,
OT signiﬁcantly improves long-term memory, thus suggesting
it enhances consolidation, a central attribute of hippocampal
function to which OT and AVP may contribute (47). Consolidation
is the processes of stabilizing a memory trace after initial
acquisition and consists of two speciﬁc phases: synaptic consol-
idation (within the ﬁrst few hours of learning or encoding) and
system consolidation, during which hippocampus-dependent
memories become independent of the hippocampus over a
period of weeks or years. Retrieval and extinction are two other
strictly connected processes associated with consolidation:
retrieval is the only way memory can be measured, and extinction
is the process by which a conditioned response diminishes over
time. To determine whether a drug is involved in consolidation or
retrieval, it can be administered before or after different phases
of training and/or testing. A careful examination of the few pub-
lished reports indicates that OT can improve memory but only
under certain conditions (Table 1): a low dose given immediately
(or at most 1 hour) after the acquisition phase (5,9,10). Similarly, a
very low SC OT dose (.1 ng/kg) given to mice performing the
object recognition task improves the consolidation of episodic
memory, and this effect is antagonized by a selective oxytocin
receptor (OTR) antagonist (5). In the wake of ﬁndings regarding
the enhancing effects of OT-like peptides on memory consolida-
tion, a recent study of Sepia ofﬁcinalis, a cephalopod mollusc
known for its remarkable learning abilities, showed that a
peripheral injection of cephalotocin (an OT analogue) 1 hour
after training facilitated long-term memory in a passive avoidance
task (7). Accordingly, intracerebral administration of OT (5 pg–
50 ng/animal) to chicks enhances retention in a dose- and time-
dependent manner, with 5 ng being the best dose when given
1 minute after acquisition (8).
Other forms of memory are improved by OT if the above
parameters are followed. For example, OT enhances memory in
the passive avoidance task when injected 30 minutes after
learning into the lateral septum of rats but not when injected
into other brain areas (Table S3 in Supplement 1) (9). The septum
is one major brain structure in which endogenous OT and AVP
exert their behavioral effects (30,48): it receives OT and AVP ﬁbers
originating from the bed nucleus of the stria terminalis and thewww.sobp.org/journal
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septal region also contributes to reference memory, particularly
the encoding and consolidation of information and/or its sub-
sequent recall (53). Finally, intraseptal OT facilitates social recog-
nition in rats (54). When acutely administered after acquisition, OT
facilitates fear extinction in a fear conditioning test (55), although
the very high ICV doses used (1 μg per rat) do not exclude the
participation of arginine vasopressin receptor 1 subtype a/
arginine vasopressin receptor 1 subtype b (V1aR/V1bR).
Response inhibition and extinction learning can also be
considered elementary elements of behavioral ﬂexibility, a set
of strategies aimed at assuring successful performance in unﬁxed
and challenging environments. Tests of behavioral ﬂexibility in
mice are represented by reversal learning and set shifting, in
which a previously learned response or rule needs to be sup-
pressed to redirect attention to a previously irrelevant stimulus or
stimulus dimension. It is worth noting that Oxtr/ mice are
impaired in the reversal phase of an appetitively motivated
T-maze test, whereas Oxtr/ (37) or Oxtr/ mice are not (36).
Such impairments can be due to perseveration or a reduced
ability to acquire or maintain a new strategy. Given the relevance
of perseveration and behavioral rigidity to human psychopathol-
ogy, we believe that the role of OT in behavioral ﬂexibility merits
particular attention. It is also worth noting that Oxtr/ mice,
which express only 50% of brain OTRs (36), show impaired
sociability but normal cognitive ﬂexibility and are not aggressive,
thus indicating that the number of OTRs affects these phenotyp-
ical manifestations. In addition to OT release, the level of OTR
expression in the brain may be a key factor in determining OT-
mediated behaviors.
A functional AVP/OT-like signaling system has been found in
the nematode Caenorhabditis elegans. Mutants worms lacking
nematocin (an AVP/OT-related neuropeptide) or its receptor were
subjected to an associative learning paradigm using a short-term
gustatory plasticity assay (56). The results suggested that defects
in the nematocin signaling cascade disrupted gustatory associa-
tive learning and the facilitated experience-driven modulation of
sodium chloride chemotaxis. Although there are few comparative
data, the ﬁndings described above indicate that the effects of OT
on memory are similar in different species.
Human Studies
In humans, OT has been preferentially administered intra-
nasally, but different studies are difﬁcult to compare for various
reasons: the limited dose range, single versus repeated admin-
istrations, and the use of different cognitive tasks.
The studies based on nonsocial stimuli (e.g., words) have
found a memory-impairing effect or none at all. A very low dose
of OT (.038 IU) had inconsistent effects on memory and mood
functions in healthy male volunteers when evaluated 1 hour after
treatment by means of attentional and visual analogue scales
tests (57). Higher and repeated doses (15 IU three times a day for
50 days) did not affect the learning of a word list but impaired
subsequent recall in six healthy subjects, a transient effect that
was the opposite to that induced by AVP (58). Similar results were
obtained in another study (59) in which the subjects received
nasal sprays of OT (40 μg, corresponding to 24 IU) 1, 24, or 48
hours before the acquisition phase of a memory test. The
impairing effect of OT on the long-term memory of healthy
subjects (evaluated by the free recall of verbal memory) has been
conﬁrmed by a study in which OT (40 μg) was administered 10
minutes before acquisition (60).www.sobp.org/journalVarious memory tests have been carried out in human healthy
subjects using social (reproduction-related words associated with
gender or faces) or nonsocial stimuli (a list of words, houses, or
neutral pictures). The administration of OT 24 IU 40 to 50 minutes
before the acquisition phase had no effect (61–63) or impaired
(64) the recall of nonsocial stimuli but impaired or improved the
recall of social stimuli: this difference could only be partially
explained by differences in the types of faces (neutral versus
emotional) or objects (houses versus sculptures and landscapes).
Apart from the study using the very low dose of .038 IU (57),
none of the human studies have used doses other than the usual
15 to 24 IU, and this has prevented the construction of a dose-
response curve. However, as animal studies suggest that the
effects of OT are dose-dependent, studies directly comparing
more than one dose (and preferably a range of doses) would be
useful. Furthermore, as OT improves memory in animals when
given within 1 hour of acquisition, it would be interesting to
investigate the human effects of OT during the consolidation
phase.
One open question is how long brain OT levels remain
elevated after intranasal administration. It has been shown that
CSF levels of the cognate peptide AVP increase for up to 80
minutes and remain above baseline levels for 100 to 120 minutes
(65). However, there are no data concerning OT itself. It is worth
noting that no convincing evidence of a direct correlation
between central and peripheral OT levels has been reported in
humans, which suggests caution when interpreting associations
between peripheral levels and psychiatric conditions. Further-
more, the lack in reliability of commercially available methods for
OT determination raises serious concerns about their validity
(66,67).
Although accumulating evidence suggests that OT plays a role
in many neuropsychiatric disorders (particularly those involving
social dysfunction, such as autism spectrum disorders, social
anxiety disorders, obsessive-compulsive disorders, attachment
disorders, depression, and schizophrenia), its therapeutic poten-
tial is still intensely debated (68). Cognitive deﬁcits are a
prominent and disabling component of schizophrenia, and the
efﬁcacy of current pharmacologic treatments is limited. Plasma
OT concentrations are lower in schizophrenic patients than in
normal subjects and negatively correlate with psychotic symp-
toms (69,70). The ﬁrst evidence of the beneﬁcial effect of OT on
memory comes from a small group of schizophrenic patients
treated with intranasal OT (20 IU) twice a day for 1 week and then
with 40 IU twice a day for a further 2 weeks (71), who showed a
striking improvement in short-term but not long-term verbal
memory as assessed by the California Verbal Learning Test and
the Letter Number Sequence. In an another study (72), intranasal
OT (24 IU) twice daily for 14 days reduced the effects of psychotic
symptoms and improved social cognition in schizophrenic
patients. However, it is currently impossible to discern how much
of the beneﬁcial effect of OT on verbal memory is due to speciﬁc
procognitive effects and how much is secondary to the OT-
induced reduction in the patients’ core schizophrenia symptoms.
Nevertheless, although the use of different cognitive tests makes
it difﬁcult to compare the studies, the positive results appear
promising.
Few studies have reported brain OT system alterations in
aging subjects or those with degenerative neurological disorders
(of which memory disturbances are a clinical hallmark). Studies of
rats (73) and monkeys (74) have found an age-related decrease
in central OTergic activity, but no human data are available.
Postmortem studies of brain tissue taken from elderly subjects
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decreased (75), increased (76), or unchanged OTergic activity (77),
thus leaving the ﬁeld open to further investigation.
Oxytocin may have a beneﬁcial effect on posttraumatic stress
disorder (PTSD). The memory impairments associated with PTSD
may be related to functional and morphological changes in the
brain structures involved in episodic memory function, including
the frontal cortex, hippocampus, and amygdala (78). An enhanc-
ing role of OT in extinction is consistent with the ﬁnding that the
intranasal administration of OT (48 IU) inhibited memory retrieval
in 43 male veterans of the Vietnam war with PTSD (79). A very
recent study (80) involved 44 healthy subjects who underwent a
conditioned fear acquisition procedure before receiving acute
treatment with OT (24 IU); 45 minutes later, they underwent
extinction training and they were tested for extinction recall after
a further 24 hours. It was found that OT facilitated extinction
recall, which supports its potential use as adjunctive treatment to
extinction-based therapies for fear-related disorders.
Although preliminary clinical trial results indicate that OT is
beneﬁcial in schizophrenic patients, much work is still needed to
advance its therapeutic development in other neuropsychiatric or
neurological disorders.The Neurochemical Substrates of OT-Induced Effects on
Learning and Memory
Although it has been clearly established that OT plays a role in
learning and memory in animal models, the cellular and molec-
ular mechanism(s) underlying its action are much less well known.
Oxytocin can inﬂuence learning and memory at different times
and in different ways (by establishing neural networks during
development, by cooperating with classical neurotransmitter
systems, and by directly mediating plasticity phenomena in target
neurons), and animal studies are beginning to provide some clues
concerning these substrates, particularly at neurochemical and
electrophysiological levels.
There is virtually no OT immunoreactivity in the developing
brain (81), and the ﬁrst exposure to OT occurs perinatally or
postnatally. Interestingly, some evidence indicates that OT plays
both neuroprotective and neurodevelopmental roles in the
postnatal period. At about the time of delivery, it temporarily
switches gamma-aminobutyric acid (GABA) neurotransmission
from its excitatory to its inhibitory form, thus potentially protect-
ing hippocampal neurons from anoxic insults (82); this protective
effect on immature cultured hippocampal neurons has recently
been conﬁrmed by an oxygen/glucose deprivation challenge (83).
It has also been elegantly shown that OT triggers the appearance
of the coherent activity pattern in the developing hippocampus
(84), thus suggesting that it plays a role in the maturation of
neuronal microcircuits. Data showing an imbalance in GABA/
glutamate synaptic contacts in cultured postnatal hippocampal
neurons obtained from Oxtr/ mice (37) also support the
possibility that OT plays a role in regulating GABA signaling at
the end of the second postnatal week, in concomitance with the
ﬁnal shift of GABA from depolarization to hyperpolarization (85).
The contribution of OT to the formation of new connections
and synaptic contacts may also inﬂuence learning and memory
processes in the mature brain. An OT-induced improvement in
hippocampus-dependent plasticity has been described in moth-
erhood (10), and this is in line with accumulating evidence that
late pregnant and lactating rats have denser populations of
hippocampal dendritic spines than virgins and that maternalexperience alters hippocampal plasticity to ensure the better care
of the pups (86). It is also worth mentioning that OT stimulation of
neurogenesis has been found in adult rat hippocampus (87).
Finally, functional magnetic resonance imaging studies have
started to shed light on the OT-induced modulation of functional
connectivity in the human brain, as extensively reviewed else-
where (88).
A number of studies of the effect of OT on basal neuro-
transmission in adult hippocampus have found an inhibitory
action mediated by the activation of GABAergic interneurons
(89–92), and a few studies have also found that OT acts on
activity-dependent hippocampal synaptic plasticity. In the medial
prefrontal cortex, OT converts long-term depression to long-term
potentiation (LTP) (93), and in the cornu ammonis 1 (CA1)
pyramidal neurons of adult rats, it prolongs the duration of LTP
(10,94). Surprisingly, this latter ﬁnding was obtained in the dorsal
hippocampus of male and female rats aged 4 to 5 weeks, a region
in which no OT ﬁbers have been found in adult female rats (95).
It can therefore be postulated that OT ﬁbers are present at
puberty and then disappear or that it is AVP that physiologically
mediates these effects. It is known that AVP plays a role in the
hippocampal activity-dependent plasticity mediated by V1aRs
and V1bRs (89,96–99), and the use of high concentrations of
agonists and antagonists in the above-mentioned studies does
not rule out the possibility of overlapping V1aR/V1bR-mediated
effects. Further studies are required to assess if OT has a direct
effect on the activity-dependent synaptic plasticity involved in
LTP and/or long-term depression (the neurobiological substrates
of memory), or if it participates in learning and memory processes
by acting on other neurotransmitters/neuromodulators.Critical Issues and Strategies
On the basis of the reviewed literature, it is still too early to
draw any deﬁnite conclusions concerning the role(s) of OT in
regulating cognitive functions such as learning and memory for a
number of reasons.
First of all, animal studies indicate that low doses of OT can
improve memory in healthy subjects only when given during the
ﬁrst phase of consolidation (within 1 hour), but it has not yet
been given to healthy humans during the consolidation phase
and so no veriﬁcation of a possible improving effect is possible.
Second, the cognitive effects of OT follow an inverted
U-shaped dose-response curve that is typical of many peptides
tested in animals, whereas studies of healthy humans have only
tested single doses or a very narrow range of doses chosen on
the basis of their ability to improve the recognition memory of
faces. Future studies using a wider range of doses could provide
more information about optimal OT doses for improving learning
and memory.
Third, most human studies have used intranasally adminis-
tered OT, which is the best noninvasive route for drugs that have
poor systemic bioavailability after oral administration. However,
nasal sprays are limited in terms of controlling dosing and
absorption and consequently drug response (4). Furthermore,
on the basis of recent data indicating that the detrimental social
consequences of intranasal OT treatment in prairie voles persisted
for much longer than the treatments themselves, we believe that
caution is required when chronically administering intranasal OT
to humans (44). Further animal studies are needed to examine
doses, timing of administration, gender-related differences in
efﬁcacy, and the developmental timing of OT therapeutics. It iswww.sobp.org/journal
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cavity structures can limit the ability to extrapolate ﬁndings from
animals to humans.
Finally, another very important issue is how OT affects
cognition in normal and impaired subjects. Many drugs only
enhance cognition in impaired animals and have no measurable
effect (or even reduce performance) in normal rodents and
nonhuman primates: no effect in a normal animal therefore does
not necessarily preclude a beneﬁcial effect in an impaired model
(100). Studies of the effects of OT in animal models of neuro-
psychiatric disorders are urgently needed and could greatly aid
the planning of clinical trials to investigate the hormone’s
potential beneﬁts in humans with psychiatric disorders.
In conclusion, there are the premises for OT to become a
successful pharmacologic treatment for patients with selected
psychiatric and neurodevelopmental disorders. Learning how OT
works in the brain will guide the transfer of its therapeutic
potential from the laboratory to the clinic.
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